IMMUNE EFFECTOR MECHANISMS IN EBV CARRYING PATIENTS

这个项目涉及EB病毒感染之间的相互作用。 正常和免疫缺陷的细胞和宿主免疫系统 人。为了更好地理解这个复杂的系统， 有必要拓宽我们对互动的认识 病毒与不同宿主细胞在体外和体内的相互作用 被病毒感染的细胞和宿主之间的相互作用。这 该项目旨在对两个层面的某些问题进行分析， 一种相互关联的方式。 该项目由以下部分组成： 一、病毒-细胞-宿主系统的分析 II.临床相关研究。 第一部分将处理：1.目前对六种蛋白质的继续研究 已知与EBV转化的B细胞有关，EBNA-1-5 和LMP；2.LCL和BL的表型相关差异 这种差异的亚型及其在识别肿瘤中的作用 前体细胞，以及靶细胞对MHC的敏感性- 限制性细胞毒性T细胞；3.效应机制 对EBV转化细胞的免疫监测；4.一些 EBV-B细胞相互作用的一些方面。 第三部分将侧重于：1.旨在实现以下目标的方法发展 体内存在潜伏的EBV感染细胞； 中国汉族人EB病毒携带B细胞的鉴定与鉴定 活体；3.急性单核细胞增多症时的效应器动员， 与静止性血清转换相比；4.EBV特异性和非特异性 免疫缺陷患者中能或不能的特异性效应分析 控制EBV潜伏感染B细胞的增殖；5.宿主- 艾滋病患者及艾滋病相关患者EB病毒-B细胞关系的研究 复合体(ARC)；6.鼻咽部抗原表达的研究 癌症。

This project deals with the interactions between EBV-infected cells and the host immune system in normal and immunodefective persons. For an improved understanding of this complex system, it is necessary to broaden our knowledge both on the interaction of the virus with different host cells in vitro and in vivo, and on the interplay between the virally infected cells and the host. This project aims at the analysis of certain questions at both levels, in a mutually interrelated way. The project consists of the following parts: I. Analysis of the virus-cell-host system II. Clinically related studies. Part I will deal with: 1. Continued study of the six proteins now known to be associated with EBV-transformed B cells, EBNA-1-5 and LMP; 2. Phenotype related differences between LCL and BL subtypes and role of such differences for identifying the tumor precursor cell of origin, and for target cell sensitivity to MHC- restricted cytotoxic T-cells; 3. Effector mechanisms mediating immune surveillance against EBV transformed cells; 4. Some aspects of the EBV-B cell interaction. Part III will focus on: 1. Methodological developments aimed at the demonstration of latently EBV-infected cells in vivo; 2. Identification and characterization of EBV carrying B-cells in vivo; 3. Effector mobilization during acute mononucleosis, compared to silent seroconversion; 4. EBV specific and non specific effector analysis in immunodefectives that can or cannot control the proliferaton of latently EBV-infected B-cells; 5. Host- EBV-B cell relationships in patients with AIDS or AIDS-related complex (ARC); 6. Antigen expression studies in nasopharyngeal carcinoma.